缺铁性贫血与静脉血栓栓塞的风险之间的关联:一个多机构的回顾性研究
Kuo-Chuan Hung1,2, Hsiu-Lan Weng3, Chih-Wei Hsu4
1Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan.
Frontiers in nutrition
|November 5, 2025
概括
缺铁性贫血 (IDA) 显著增加静脉血栓塞栓症 (VTE) 的风险,特别是在诊断后的几个月内. 反应性血栓细胞瘤似乎调解了这种升高的静脉瘤风险的很大一部分.
科学领域:
- 血液学 血液学 血液学
- 心血管医学 心血管医学
- 营养科学 营养科学
背景情况:
- 缺铁性贫血 (IDA) 是全球最常见的营养缺乏症,影响了三分之一的人口.
- IDA与静脉血栓塞栓症 (VTE) 之间的联系尚不清楚.
- 本研究使用现实世界的数据调查了IDA和VTE风险之间的关联.
研究的目的:
- 评估IAD与发展VTE的风险之间的关系.
- 确定与IDA相关的特定VTE亚型和时间框架.
- 探索IDA-VTE协会中的潜在调解因素,如血栓细胞瘤.
主要方法:
- 一项使用TriNetX平台 (2010-2023) 的回顾性队列研究.
- 180,484个倾向匹配对将IDA患者与皮肤炎/湿疹对照进行了比较.
- 对1年VTE风险,死亡率,ICU入院,上肢血栓形成和血栓细胞形成的分析.
主要成果:
- 在1年内,IDA患者的VTE风险增加了75% (HR 1.75).
- 肺栓塞的风险显著更高 (HR2.05),在诊断后的前3个月内风险达到峰值.
- 除了血栓塞瘤病例外,静脉瘤风险减弱 (HR 1.19),表明通过反应性血栓塞瘤中介. 上肢血栓形成的频率是上肢血栓形成的2.5倍.
结论:
- IDA是VTE的重要,可修改的风险因素.
- 建议IDA患者进行临床警和预防策略,特别是在诊断后的早期.
- 反应性血栓细胞分裂在介导IAD相关的VTE风险方面发挥着作用.
相关概念视频
Venous Thrombosis I: Introduction
335
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
335
Venous Thrombosis III: Interprofessional Care
273
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
273
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
282
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
282
Venous Thrombosis IV: Nursing Management
191
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
191
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


